Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Barclays PLC

Barclays PLC raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 42.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,671 shares of the company's stock after purchasing an additional 34,533 shares during the quarter. Barclays PLC owned 0.20% of Structure Therapeutics worth $3,138,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after purchasing an additional 312 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after acquiring an additional 553 shares in the last quarter. LPL Financial LLC increased its position in shares of Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after acquiring an additional 646 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after purchasing an additional 843 shares during the period. Finally, Money Concepts Capital Corp increased its holdings in Structure Therapeutics by 4.2% during the 4th quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after purchasing an additional 848 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GPCR. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday. They issued a "buy" rating and a $60.00 price target on the stock. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $78.63.

Structure Therapeutics Stock Down 0.9 %

Shares of Structure Therapeutics stock traded down $0.24 during trading on Friday, reaching $27.09. The company's stock had a trading volume of 739,761 shares, compared to its average volume of 920,944. The company has a market capitalization of $1.55 billion, a P/E ratio of -36.61 and a beta of -1.35. Structure Therapeutics Inc. has a 12-month low of $13.22 and a 12-month high of $62.74. The business has a 50 day moving average price of $20.52 and a 200-day moving average price of $27.46.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Research analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.